Roflumilast Cream (ARQ-151)

Roflumilast cream (ARQ-151) is being investigated for the treatment of atopic dermatitis.

  • Roflumilast cream is uniquely formulated as an emollient, water-based (~48% water) cream without fragrances, propylene glycol, isopropyl alcohol, or ethanol
  • Roflumilast cream contains an exclusive emulsifier designed to maintain epidermal intercellular lipids and is adjusted to a stratum corneum pH, at which the skin normally functions
  • Ongoing clinical trials are investigating roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis

Roflumilast Cream (ARQ-151) in Atopic Dermatitis


  • Atopic dermatitis is a common, chronic inflammatory skin disease affecting both children and adults1
  • Itch is the most burdensome symptom, causing patients to experience substantially reduced quality of life and sleep disturbances2
  • The skin barrier is typically compromised in atopic dermatitis3
  • Topical corticosteroids and emollients are the standard of care3
  • Steroids are not suitable for long-term use, and children are at risk of greater systemic absorption3


  • Elevated PDE4 levels are found in the keratinocytes of individuals with atopic dermatitis3
  • Inhibition of PDE4 decreases inflammatory response and pruritus3,4
  • Roflumilast cream (ARQ-151) is a selective, highly potent5* PDE4 inhibitor being investigated as a treatment for atopic dermatitis
  • *In vitro data. Clinical efficacy claims cannot be made.
Skin with atopic dematitis.

Clinical Program Results

A phase 2 study has been completed (NCT03916081)6

Infographic showing eligibility, 4 weeks dosing, and endpoints of phase 2 study.

BSA, body surface area; EASI, Eczema Area and Severity Index; EASI-50, Eczema Area and Severity Index 50% improvement; EASI-75, Eczema Area and Severity Index 75% improvement; QD, once daily; vIGA-AD, Validated Investigator’s Global Assessment for Atopic Dermatitis; WI-NRS, Worst Itch Numeric Rating Scale.

Two phase 3 studies (INTEGUMENT-1/-2) are ongoing for roflumilast cream in atopic dermatitis (NCT04773587 and NCT04773600)7

Infographic showing eligibility, 4 week dosing, and endpoints of phase 3 studies.

aIGA success was defined as a score of 0 or 1 (clear or almost clear) with at least a 2-grade improvement from baseline.
EASI-75, Eczema Area and Severity Index 75% improvement; IGA, Investigator's Global Assessment; QD, once daily; vIGA-AD, Validated Investigator's Global Assessment for Atopic Dermatitis; WI-NRS, Worst Itch Numeric Rating Scale.

A phase 3 trial of roflumilast cream 0.05% in pediatric patients aged 2-5 years is ongoing (INTEGUMENT-PED: NCT04845620)

A phase 3 long-term study is ongoing (INTEGUMENT-OLE: NCT04804605)


1. Bieber. Ann Dermatol. 2010;22:125-137. 2. Silverberg et al. Ann Allergy Asthma Immunol. 2018;121:340-347. 3. Nygaard et al. Dermatology. 2017;233:333-343. 4. Bäumer et al. Inflamm Allergy Drug Targets. 2007;6:17-26. 5. Dong et al. J Pharmacol Exp Ther. 2016;358:413-422. 6. Gooderham et al. Presented at: 29th European Academy of Dermatology and Venereology Congress; October 29-31, 2020; Virtual. 7. Data on file, Arcutis Biotherapeutics.


The information contained in this website has been developed by Arcutis Medical Affairs and is intended for healthcare professionals (HCPs) only.

You are now leaving the Arcutis medical affairs website. Arcutis Biotherapeutics is not responsible for the content of linked sites.

Doximity social icon.
Doximity social icon.